$4.47
10.79% yesterday
Nasdaq, Jul 16, 10:15 pm CET
ISIN
US68621F1021
Symbol
ORGO

Organogenesis Holdings Target price 2025 - Analyst rating & recommendation

Organogenesis Holdings Classifications & Recommendation:

Buy
89%
Hold
11%

Organogenesis Holdings Price Target

Target Price $6.63
Price $4.47
Potential
Number of Estimates 6
6 Analysts have issued a price target Organogenesis Holdings 2026 . The average Organogenesis Holdings target price is $6.63. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 8 Analysts recommend Organogenesis Holdings to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Organogenesis Holdings stock has an average upside potential 2026 of . Most analysts recommend the Organogenesis Holdings stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 482.04 487.36
11.29% 1.10%
EBITDA Margin 8.00% 10.80%
24.17% 35.08%
Net Margin -0.20% -0.80%
117.06% 310.25%

5 Analysts have issued a sales forecast Organogenesis Holdings 2025 . The average Organogenesis Holdings sales estimate is

$487m
Unlock
. This is
6.23% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$524m 14.19%
Unlock
, the lowest is
$441m 3.76%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $482m 11.29%
2025
$487m 1.10%
Unlock
2026
$536m 9.93%
Unlock
2027
$579m 8.02%
Unlock

5 Analysts have issued an Organogenesis Holdings EBITDA forecast 2025. The average Organogenesis Holdings EBITDA estimate is

$52.6m
Unlock
. This is
133.61% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$54.6m 142.34%
Unlock
, the lowest is
$50.2m 122.71%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $38.5m 38.19%
2025
$52.6m 36.56%
Unlock
2026
$69.7m 32.36%
Unlock
2027
$96.4m 38.36%
Unlock

EBITDA Margin

2024 8.00% 24.17%
2025
10.80% 35.08%
Unlock
2026
13.00% 20.37%
Unlock
2027
16.65% 28.08%
Unlock

5 Organogenesis Holdings Analysts have issued a net profit forecast 2025. The average Organogenesis Holdings net profit estimate is

$-3.9m
Unlock
. This is
81.01% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-3.7m 81.74%
Unlock
, the lowest is
$-4.0m 80.42%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-940k 118.99%
2025
$-3.9m 312.77%
Unlock
2026
$25.2m 750.26%
Unlock
2027
$41.4m 64.09%
Unlock

Net Margin

2024 -0.20% 117.06%
2025
-0.80% 310.25%
Unlock
2026
4.71% 688.75%
Unlock
2027
7.15% 51.80%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.01 -0.03
125.00% 200.00%
P/E negative
EV/Sales 0.83

5 Analysts have issued a Organogenesis Holdings forecast for earnings per share. The average Organogenesis Holdings EPS is

$-0.03
Unlock
. This is
81.25% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.03 81.25%
Unlock
, the lowest is
$-0.03 81.25%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.01 125.00%
2025
$-0.03 200.00%
Unlock
2026
$0.20 766.67%
Unlock
2027
$0.33 65.00%
Unlock

P/E ratio

Current -27.91 24.67%
2025
-131.70 422.88%
Unlock
2026
20.26 115.38%
Unlock
2027
12.35 39.04%
Unlock

Based on analysts' sales estimates for 2025, the Organogenesis Holdings stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.00 23.46%
2025
0.83 6.07%
Unlock
2026
0.75 9.04%
Unlock
2027
0.70 7.42%
Unlock

P/S ratio

Current 1.23 43.49%
2025
1.05 5.87%
Unlock
2026
0.95 9.04%
Unlock
2027
0.88 7.43%
Unlock

Current Organogenesis Holdings Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Cantor Fitzgerald
Locked
Locked
Locked Jul 15 2025
Morgan Stanley
Locked
Locked
Locked Mar 05 2025
Analyst Rating Date
Locked
Cantor Fitzgerald:
Locked
Locked
Jul 15 2025
Locked
Morgan Stanley:
Locked
Locked
Mar 05 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today